Latest Breaking News On - Prior to federated kaufmann fund - Page 1 : comparemela.com

Published: Dec 17, 2020 LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. We are delighted to welcome Dr. Gray to Keros’ Board of Directors,” said President and Chief Executive Officer Jasbir Seehra, Ph.D. Her deep experience guiding both growing and commercial-stage companies as a board member, coupled with her scientific and financial acumen, will be a tremendous asset as we continue to further advance multiple assets in the clinic.

United statesMary ann grayJasbir seehraJulia balanovaKeros therapeutics incKaufmann fundCompany nasdaqNeorx corporationGray strategic advisorsRapt therapeutics incNorthwestern university medical schoolPrior to federated kaufmann fundBioatla incUniversity of south carolinaYale university school of medicineSarepta therapeutics inc